regardless of promising clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable difficulty from pharmacy benefit managers. Such organizations are typically building limitations to access, including high cost requirements and prior authorization that restrict patien